Skip to main content
. 2022 Oct 7;13:992819. doi: 10.3389/fimmu.2022.992819

Table 4.

Incidence Rate Ratio and Hazard Ratio of the Risk of systemic ADs between IBT and non-IBT group.

Event Person Year IncidenceRate† IRR aHR
Polymyositis/dermatomyositis graphic file with name fimmu-13-992819-i007.jpg graphic file with name fimmu-13-992819-i008.jpg
IBT Group 0 73009.17 0.00 N.A N.A
Non-IBT Group 7 474442.69 1.48 Ref. Ref.
Rheumatoid arthritis
IBT Group 18 72946.54 24.68 1.04 (0.63-1.70) 0.91 (0.55-1.52)
Non-IBT Group 113 474132.51 23.83 Ref. Ref.
Primary Sjogren’s syndrome
IBT Group 28 72940.62 38.39 1.12 (0.75-1.68) 1.06 (0.70-1.60)
Non-IBT Group 162 474072.65 34.17 Ref. Ref.
Systemic lupus erythematosus
IBT Group 2 73000.58 2.74 0.39 (0.09-1.64) 0.38 (0.09-1.62)
Non-IBT Group 33 474384.46 6.96 Ref. Ref.
Systemic sclerosis
IBT Group 1 73006.74 1.37 0.81 (0.10-6.49) 0.94 (0.11-7.97)
Non-IBT Group 8 474436.63 1.69 Ref. Ref.
Systemic vasculitis
IBT Group 0 73009.17 0.00 N.A N.A
Non-IBT Group 1 474444.39 0.21 Ref. Ref.

IR, incidence rate was incidences of per 100,000 person-years. HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; NA, not available.